Harvard Bioscience (HBIO) Net Cash Flow (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Net Cash Flow data on file, last reported at -$1.3 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$1.3 million, down 217.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 25.93% YoY), and the FY2025 annual result was $3.6 million, up 10314.29% from the prior year.
• Net Cash Flow retreated to -$1.3 million in Q1 2026 per HBIO's latest filing, from $1.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $1.8 million in Q4 2025 and troughed at -$2.4 million in Q1 2022.
• A 5-year average of -$54764.7 and a median of -$98000.0 in 2024 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 1889.8% in 2025 and fell as far as 458.94% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$286000.0 in 2022, then sank by 205.59% to -$874000.0 in 2023, then soared by 88.79% to -$98000.0 in 2024, then surged by 1889.8% to $1.8 million in 2025, then plunged by 173.6% to -$1.3 million in 2026.
• Business Quant data shows HBIO's Net Cash Flow at -$1.3 million in Q1 2026, $1.8 million in Q4 2025, and -$542000.0 in Q3 2025.